Ceradyne reported significant declines in sales, net income, and gross margins compared to the previous year, alongside lowered guidance for 2012. Delays in key military contracts and ongoing challenges in the solar business further exacerbate short-term uncertainties. Despite management's focus on long-term strategies, the immediate outlook suggests substantial negative pressure on the stock.

[-2]